CANF vs CBUS

Can-Fite Biopharma Ltd vs Cibus, Inc. — Valuation Comparison 2026

CANF

Biotechnology
Can-Fite Biopharma Ltd
Quality
2.2
out of 10
Value Trap
6
SAFE
Price
$3.36
Last close
Models
9/13
Active
VS

CBUS

Biotechnology
Cibus, Inc.
Quality
5.7
out of 10
Value Trap
33
LOW
Price
$1.45
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CANF Fair ValueCANF Upside CBUS Fair ValueCBUS Upside
Bayesian DCF Intrinsic $0.89 -73.5% $0.39 -73.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.39 -88.5% $2.01 +38.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $2.83 -15.6% $4.41 +204.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CANF vs CBUS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CANF vs CBUS — Which Stock Is More Undervalued?

CBUS scores higher with a 5.7/10 quality rating vs CANF's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Can-Fite Biopharma Ltd (CANF) and Cibus, Inc. (CBUS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CANF currently trades at $3.36 with a QOC of 2.2/10, while CBUS trades at $1.45 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).